AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04616963
Drug: Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation.
Trial: NCT04616963
Drug: Emtricitabine Tenofovir Alafenamide 200/25 mg
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation
Trial: NCT01838317
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00953667
Drug: Immediate Release Niacin, Extended Release Niacin, Endotoxin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).
Trial: NCT02726828
Drug: intrathecal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg intrathecal morphine1 ml volume.
Trial: NCT02726828
Drug: intrathecal ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg intrathecal ketamine in 1ml volume.
Trial: NCT02726828
Drug: intrathecal morphine + ketamine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and intrathecal morphine + ketamine 0.3 mg and 0.1 mg/kg respectively in 1 ml volume.
Trial: NCT03038321
Drug: Tavanic
RxNorm normalized name: Cassia javanica whole extract
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: levofloxacin 500 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
Trial: NCT00730158
Drug: KD018
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Trial: NCT00730158
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Trial: NCT02290470
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Drug: Olanzapine 10 mg oral~* Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.~* Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy).
Trial: NCT02290470
Drug: Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
Trial: NCT00516321
Drug: eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25, 50, 75, 100 mg tablets taken once daily orally
Trial: NCT00984009
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1
Trial: NCT00984009
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of 0.6 mg colchicine administered with grapefruit juice at 7:15 a.m. on Day 18 after an overnight fast of at least 10 hours.
Trial: NCT02447965
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Using ultrasound guidance bupivacaine will be injected into the active group's rectus abdominis sheath.
Trial: NCT00405080
Drug: GW679769 (Casopitant) oral tablets
RxNorm normalized name: maropitant Oral Tablet
DrugBank: Maropitant (DB11427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive three 50 mg tablets for the dose of 150 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
Trial: NCT00405080
Drug: Rifampin oral capsules
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin capsules will be available with dose strength of 300 mg. Subjects will receive two 300 mg capsules for the dose of 600 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
Trial: NCT03360266
Drug: 5% Sodium Fluoride Varnish
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ffor children with ECC, this varnish effectively remineralizes the white spot lesion
Trial: NCT02738008
Drug: ARC-520 Injection
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV injection
Trial: NCT02738008
Drug: entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
Trial: NCT02738008
Drug: tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
Trial: NCT02738008
Drug: antihistamine
RxNorm normalized name: Antihistamine
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
Trial: NCT01388517
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1% tacrolimus ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
Trial: NCT01388517
Drug: Calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.0003% calcitriol ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
Trial: NCT02865681
Drug: Menopur
RxNorm normalized name: Menopur
DrugBank: Menotropins (DB00032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal versus injectable
Trial: NCT02865681
Drug: Synarel
RxNorm normalized name: Synarel
DrugBank: Nafarelin (DB00666)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nasal
Trial: NCT02865681
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02865681
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01388517
Drug: Petrolatum
RxNorm normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Petrolatum ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
Trial: NCT00781378
Drug: rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rt-PA 100 mg continuous intravenous infusion for 2 hours
Trial: NCT00781378
Drug: rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rt-PA 50 mg continuous intravenous infusion for 2 hours
Trial: NCT01376089
Drug: Iodixanol
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodixanol 320 mg I/mL as a single iv. administration.
Trial: NCT01376089
Drug: Iopamidol
RxNorm normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.
Trial: NCT03262935
Drug: (vic-)trastuzumab duocarmazine
RxNorm normalized name: Trastuzumab duocarmazine
DrugBank: Trastuzumab duocarmazine (DB16342)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous SYD985, Q3W
Trial: NCT03428958
Drug: NUC-3373
RxNorm normalized name: NUC-7738
DrugBank: NUC-7738 (DB19148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUC-3373
Trial: NCT03428958
Drug: NUFOX
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NUC-3373 + oxaliplatin
Trial: NCT03428958
Drug: NUFOX + EGFR inhibitor
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUC-3373 + oxaliplatin + cetuximab/panitumumab
Trial: NCT03428958
Drug: NUFIRI + EGFR inhibitor
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUC-3373 + irinotecan + cetuximab/panitumumab
Trial: NCT03428958
Drug: NUC-3373 + bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NUC-3373 + bevacizumab
Trial: NCT00523146
Drug: Kanion Capsule
RxNorm normalized name: Arsenite anion
DrugBank: Arsenite ion (DB18509)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02639091
Drug: BAY 94-9343
RxNorm normalized name: Anti-mesothelin antibody-drug conjugate BAY 94-9343
DrugBank: Anetumab ravtansine (DB14809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 1 of the study, anetumab ravtansine (BAY 94-9343) will be administered by 1-hour IV infusion with a starting dose of 5.5mg/kg(BW) on Day 1 of every treatment cycle (Q3W).~In Part 2 of the study, anetumab ravtansine (BAY 94-9343) will be administered on Day 2 of Cycle 1 and then on Day 1 of Cycle 2 and all subsequent cycles (Q3W)
Trial: NCT02639091
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered at the dose of 500 mg/m2 body surface area (BSA) by 10-minute IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
Trial: NCT02639091
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered at the dose of 75 mg/m2 (BSA) by 2-hour IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
Trial: NCT01599104
Drug: Olmesartan
RxNorm normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg capsule one daily
Trial: NCT00549640
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
Trial: NCT01682408
Drug: Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
Trial: NCT01682408
Drug: Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
DrugBank: Tamatinib (DB07159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
Trial: NCT01682408
Drug: Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
Trial: NCT00994097
Drug: NGR-hTNF
RxNorm normalized name: NGR-hTNF
DrugBank: Tengonermin (DB16689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
Trial: NCT00994097
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
Trial: NCT00994097
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine: 1,250 mg/m² intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
Trial: NCT00994097
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed: 500 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
Trial: NCT04479865
Drug: Aricept 5mg Tablet
RxNorm normalized name: Aricept 5mg Tablet
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet once daily
Trial: NCT04479865
Drug: Aricept 10mg Tablet
RxNorm normalized name: Aricept 10mg Tablet
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet once daily
Trial: NCT04479865
Drug: DA-5207 150mg
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 patch once weekly
Trial: NCT01225211
Drug: Lumacaftor
RxNorm normalized name: Lumacaftor
DrugBank: Lumacaftor (DB09280)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01225211
Drug: Ivacaftor
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet.
Trial: NCT01682408
Drug: Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 150mg mannitol based 38% drug loaded tablet(batch variant B)
Trial: NCT01682408
Drug: Ranitidine
RxNorm normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine
Trial: NCT04479865
Drug: DA-5207 170mg
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 patch once weekly
Trial: NCT00019747
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
Trial: NCT01098344
Drug: Notch signaling pathway inhibitor MK0752
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01098344
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00803283
Drug: Hydromprphone Hydrochloride (HCl) OROS
RxNorm normalized name: Hydromorphone Hydrochloride
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
Trial: NCT00091650
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00687167
Drug: Zonisamide 100 mg Capsule
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
Trial: NCT00687167
Drug: Zonisamide (Zonegran®) 100 mg Capsule
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
Trial: NCT01225211
Drug: Lumacaftor Placebo
DrugBank: Lumacaftor (DB09280)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet.
Trial: NCT01225211
Drug: Ivacaftor Placebo
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Matching placebo tablet.
Trial: NCT00803283
Drug: Morphine Sustain Release (SR)
RxNorm normalized name: morphine Extended Release Oral Tablet
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive morphine SR 8 mg every24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
Trial: NCT00646191
Drug: adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
Trial: NCT00646191
Drug: adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40 mg weekly through Week 48 (OL Week 12 - 48)
Trial: NCT01655758
Drug: 0.5% timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01655758
Drug: timolol-dorzolamide fixed combination
RxNorm normalized name: dorzolamide / timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00646191
Drug: adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg W0, 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
Trial: NCT03628391
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: haloperidol for ICU delirium, titrated on validated screening tool-based diagnosis
Trial: NCT00636155
Drug: cenersen sodium
RxNorm normalized name: Cenersen
DrugBank: Cenersen (DB15455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4
Trial: NCT00636155
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 on day 2
Trial: NCT00636155
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m2 on days 2, 3, and 4
Trial: NCT00286156
Drug: Rapamune
RxNorm normalized name: Rapamune
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care
Trial: NCT00935961
Drug: RAD001 + docetaxel + cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously every 3 weeks). Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle. Patients will be followed for toxicity for 30 days after the last dose of RAD001. Patients should undergo re-staging imaging studies within 2 - 6 weeks after the final treatment with cisplatin/docetaxel. After the completion of induction chemotherapy and the 30-day observation period after treatment, patients are removed from the study.
Trial: NCT01655758
Drug: Latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01655758
Drug: Travoprost
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01655758
Drug: Bimatoprost
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02474563
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants receiving Bortezomib 1.3 milligram per square meter (mg/m2) will be observed in this study.
Trial: NCT02474563
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receiving Melphalan 9 mg/m\^2 will be observed in this study.
Trial: NCT02474563
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receiving Prednisone 60 mg/m\^2 will be observed in this study.
Trial: NCT01715168
Drug: ATI-0918
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no